Publications

Update of Dalbavancin Activity in the USA: Report from the SENTRY Program (2011), Lead author: Jones RN, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2011: USA Surveillance Report, Lead author: Ross JE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of Ceftaroline and Comparator Agents Tested Against Contemporary (2010) Pathogens Commonly Associated With Respiratory Tract Infections in Asia-Pacific Countries and South Africa, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested Against Bacteria Collected from Patients with Community-Acquired Respiratory Tract Infections in the USA (2008-2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

New OXY-variants from Klebisiella oxytoca Bloodculture Clinical Isolates Collected in USA Hospitals, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Oritavancin Using Fastidious and non-Fastidious Gram-Positive Organisms, Lead author: Holliday, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Dalbavancin Using Fastidious and non-Fastidious Gram- Positive Organisms, Lead author: Holliday, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Ceftaroline-Avibactam Tested Against Contemporary Clinical Isolates from USA Medical Centers (2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Avibactam Reverts the Ceftazidime (CAZ) MIC₉₀ of a Recent Set of European Clinical Isolates of Gram-negative Bacteria Back to the Epidemiological Cut-off Value, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Spectrum and Potency of Ceftaroline-Avibactam Tested Against ESBL-Phenotype and Carbapenem-Resistant Enterobacteriaceae Collected from USA Hospitals (2009-2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of BAL30072, Alone and in Combination with Meropenem Tested Against Gram-Negative Bacteria Causing Serious Infections in Hospitals from China, India, Latin America and South East Asia-Pacific, Lead author: Rhomberg PR, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of the Novel Antimicrobial Ceftolozane/Tazobactam Tested Against Contemporary Clinical Strains from USA Hospitals (2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Six Seachaid Pharmaceuticals Investigational Compounds Tested against Gram-positive Strains, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity and Spectrum of a Seachaid Pharmaceuticals Investigational Compound (SP2078) Tested against Gram-positive Pathogens, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Time-kill and Post-antibiotic-effect studies of a Seachaid Pharmaceuticals Investigational Compound (SP2078) Against Wildtype and Multidrug-resistant Pathogens, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

In Vitro Activity of KPI-10 Tested Against a Global Collection of Acinetobacter spp. Including Multi-Drug Resistant (MDR) Strains, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

KPI-10 In Vitro Activity Tested Against Pathogens Commonly Associated with Community-Acquired Bacterial Pneumonia Infections, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

KPI-10, a Novel Fluoroquinolone Tested Against Neisseria gonorrhoeae including Ciprofloxacin Non-Susceptible and Penicillin Non-Susceptible Strains, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

In Vitro Activity of KPI-10 Tested Against Pathogens Commonly Associated with Urinary Tract infections, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of RPX2003/RPX7009 (RPX3/9), a Carbapenem Combined with a Novel &#223-lactamase Inhibitor Tested Against Clinical Isolates Producing Defined Enzymes, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Pre-clinical Evaluation of a Carbapenem/ß-Lactamase Inhibitor Combination (RPX2003/RPX7009) Tested Against Serine-carbapenemase-producing Pathogens, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of MK-3118, a New Oral Glucan Synthase Inhibitor, Tested Against Aspergillus spp. using Two Reference Broth Microdilution Methods, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

New CLSI Clinical Breakpoints and Epidemiological Cutoff Values Applied to Characterize Resistance in the SENTRY Antifungal Surveillance Program (2010-2011), Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Comparative Potencies of Contemporary Generic Vancomycin Lots; in-vitro Assay results from Nine Products and a Reference Reagent-Grade Sample, Lead author: Jones RN, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Use of Check-points Microarray for Beta-lactamase (BL) Detection Among Enterobacteriaceae (ENT) Bacteremia Isolates from USA Hospitals, Lead author: Castanheira M, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Streptococcus pneumoniae isolates from Latin America, Lead author: Sader HS, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Antimicrobial activity of ceftaroline and comparator agents tested against contemporary (2010) Staphylococcus aureus, including MRSA isolates, from Latin America, Lead author: Sader HS, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Antimicrobial activity of ceftaroline/avibactam tested against clinical Enterobacteriaceae isolates carrying multiple &#223-lactamases from USA medical centers, Lead author: Sader HS, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Interim Susceptibility Testing for Ceftaroline (CPT), a Novel MRSA-Active Cephalosporin: Selecting Potent Surrogate &#223-Lactam Markers to Predict CPT Activity against Clinically Indicated Species, Lead author: Jones RN, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Candida famata as a Cause of Invasive Candidiasis: Misidentification in Two Global Surveillance Systems, Lead author: Castanheira M, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Contemporary Potencies of Minocycline (MIN) and Tetracycline (TET) Tested Against Gram-positive Pathogens: SENTRY Program Results using CLSI and EUCAST Breakpoint Criteria, Lead author: Jones RN, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Influence of Surfactant (Polysorbate-80) on Susceptibility Testing Results for the Polymyxins Using Broth Microdilution Methods, Lead author: Sader HS, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Educational Susceptibility (S) Testing as a Critical Component of Laboratory Proficiency Programs: American Proficiency Institute (API) Results for 2007-2010, Lead author: Jones RN, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Outbreak of KPC-2-producing Klebsiella pneumoniae isolates in two Texas hospitals: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Antimicrobial Activity of the New Cephalosporin Ceftaroline Tested Against Bacterial Isolates FromSurgical Skin and Skin Structure Infections in USA Medical Centers (2008-2011), Lead author: Sader HS, presented at 32nd annual Surgical Infection Society (SIS), April 18 – 21, 2012, Dallas, Texas

Activity of ceftaroline/avibactam tested against multidrug-resistant Enterobacteriaceae and methicillin-resistant Staphylococcus aureus collected from USA hospitals in 2011, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial spectrum and potency of ceftaroline/avibactam when tested against bacterial isolates from complicated urinary tract infections in the United States, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of PTK 0796 (omadacycline) tested against Gram-positive organisms isolated from European hospitals in 2011, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

In vitro evaluation of antimicrobial spectrum and determination of optimal MIC test conditions for the novel protein epitope mimetics antibiotic POL7080, Lead author: Dale, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Spectrum and potency of ceftaroline against leading pathogens causing skin and skin-structure infections in Europe and South Africa, 2010, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Ceftaroline activity against clinical isolates from United States hospitals: results from the 2011 Assessing Worldwide Antimicrobial Resistance Evaluation programme, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Spectrum and potency of ceftaroline against leading pathogens causing community acquired respiratory tract infections in Europe and South Africa, 2010, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Streptococcus pneumoniae from Europe and South Africa, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Characterisation of resistance mechanisms and epidemiology of Enterobacteriaceae collected during a phase II clinical trial for ceftazidime avibactam, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Prevalence of ESBL and carbapenemase-producing phenotypes of Enterobacteriaceae identified in the 2010 AWARE surveillance programme, Lead author: Krause, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Oritavancin activity tested against Staphylococcus aureus responsible for documented infections in European hospitals, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Update on daptomycin activity and spectrum tested against Gram-positive organisms collected in 2011 from European medical centres, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin structure infection obtained during a phase II clinical trial, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Adjusting EUCAST zone diameter breakpoints for Haemophilus influenzae on the Mueller-Hinton Fastidious media, Lead author: Ahman, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Contemporary doxycyline and tetracycline susceptibility testing using CLSI and EUCAST criteria for Gram-positive pathogens: results from SENTRY programme, Lead author: Jones RN, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK